RESULTS	The cumulative probability of developing clinically definite multiple sclerosis was significantly lower in the IVIg treatment group compared with the placebo group ( rate ratio , 0.36 [ 95 % confidence interval , 0.15-0 .88 ] ; P = .03 ) .\